Induction of complete remission in T-cell acute lymphoblastic leukemia with deoxycoformycin (dcf) and 9-beta-D-arabinofuranosyladenine (ara-A).
D000328:Adult; D000954:Antigens, Surface / Q000032:analysis; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D003070:Coformycin / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000633:toxicity; D004334:Drug Administration Schedule; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male; D015649:Pentostatin; D012263:Ribonucleosides / Q000008:administration & dosage*; D013601:T-Lymphocytes / Q000276:immunology; D014740:Vidarabine / Q000008:administration & dosage* / Q000633:toxicity
D000954:Antigens, Surface; D000970:Antineoplastic Agents; D012263:Ribonucleosides; D003070:Coformycin; D015649:Pentostatin; D014740:Vidarabine